Literature DB >> 7586746

Distinct production of autoantibodies to nuclear components in ulcerative colitis and in Crohn's disease.

D Reumaux1, C Mézière, J F Colombel, P Duthilleul, S Mueller.   

Abstract

Despite extensive research, the pathogenesis of inflammatory bowel disease (IBD) is still unclear. Immunological disorders have been described in patients with both Crohn's disease (CD) and ulcerative colitis (UC). In this work serum samples collected from 58 patients with CD and 55 patients with UC were tested in ELISA against a panel of nuclear and cytoplasmic proteins and peptides in order to determine whether specific autoantibodies are produced in these patients. Low levels of IgG antibodies to histones H1, H2A, H2B, H3, and H4, to Hsp-70 and ubiquitin stress proteins, Ro/SSA and La/SSB proteins and myosin were detected in some of these sera. In contrast, the following antibodies of IgG isotype could be much more frequently demonstrated: antibodies to ubiquitinated H2A (U-H2A) peptide T4 (51.7% in CD; 18.2% in UC), antibodies to the zinc-finger peptide F2 of poly-(ADP-ribose polymer)ase (PARP) involved in DNA repair (58.6% in CD; 25.5% in UC) and actin antibodies (43.1% in CD; 7.3% in UC). In a follow-up study of 12 patients with CD and UC (75 additional samples), we found IgG antibodies to several histone peptides occurring essentially in the serum of patients with CD. Although we found no obvious correlation between the presence or level of these various antibodies and C-reactive protein, or the location of the disease, in a number (but not all) of patients, we observed a strikingly good relationship between antibodies to histone peptides, U-H2A peptide T4, and PARP peptide F2 and the Crohn's disease activity index. The mechanism of induction of these antibodies still remains obscure.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7586746     DOI: 10.1006/clin.1995.1162

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  9 in total

1.  Abdominal aortitis associated with Crohn's disease.

Authors:  Eugeni Domènech; Esther Garcia-Planella; Angel Olazábal; Jordi Sánchez-Delgado; Yamile Zabana; Isabel Bernal; Míriam Mañosa; Alejandro Olivé; Miquel A Gassull
Journal:  Dig Dis Sci       Date:  2005-06       Impact factor: 3.199

2.  Antinuclear autoantibodies in patients with inflammatory bowel disease. High prevalence in first-degree relatives.

Authors:  C Folwaczny; N Noehl; S P Endres; W Heldwein; K Loeschke; H Fricke
Journal:  Dig Dis Sci       Date:  1997-08       Impact factor: 3.199

3.  Molecular cloning of a Bacteroides caccae TonB-linked outer membrane protein identified by an inflammatory bowel disease marker antibody.

Authors:  B Wei; H Dalwadi; L K Gordon; C Landers; D Bruckner; S R Targan; J Braun
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

Review 4.  Epigenetic histone code and autoimmunity.

Authors:  Jürgen Dieker; Sylviane Muller
Journal:  Clin Rev Allergy Immunol       Date:  2010-08       Impact factor: 8.667

5.  Antisecretory factor suppresses intestinal inflammation and hypersecretion.

Authors:  E Johansson; E Jennische; S Lange; I Lönnroth
Journal:  Gut       Date:  1997-11       Impact factor: 23.059

6.  Colonic bacteria express an ulcerative colitis pANCA-related protein epitope.

Authors:  O Cohavy; D Bruckner; L K Gordon; R Misra; B Wei; M E Eggena; S R Targan; J Braun
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

7.  Analysis of serum antibodies in patients suspected of having inflammatory bowel disease.

Authors:  Troy D Jaskowski; Christine M Litwin; Harry R Hill
Journal:  Clin Vaccine Immunol       Date:  2006-06

Review 8.  Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease.

Authors:  Pal Pacher; Csaba Szabo
Journal:  Am J Pathol       Date:  2008-06-05       Impact factor: 4.307

9.  ADP-ribosylation signalling and human disease.

Authors:  Luca Palazzo; Petra Mikolčević; Andreja Mikoč; Ivan Ahel
Journal:  Open Biol       Date:  2019-04-26       Impact factor: 6.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.